The application relates to triazole derivatives of the general Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The compounds are useful for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD)
该申请涉及一般式(I)的三唑衍
生物,它们结合到
溶血磷脂酸受体1(LPAR1)并作为LPAR1的拮抗剂。这些化合物通过结合LPAR1用于治疗疾病和/或病况,包括纤维化和肝脏疾病,如非
酒精性脂肪性肝炎(NASH),间质性肺病(ILD)或慢性肾脏疾病(CKD)。